In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

The dividend remains well supported -- the REIT reported funds from operations ( FFO) per share of $1.05 during the first ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Artificial intelligence trading tools that analyze reams of data and build portfolios are already shaking up Wall Street. But ...

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

With Main Street investors now able to trade as fast as some qualitative hedge funds, seismic changes could be ahead for the ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

New stores are opening across the city at an impressive pace, many of them in locations now newly accessible to certain ...

And with an eye to today’s Apple’s Worldwide Developers Conference, investors are hoping that technology stocks will help ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

(Bloomberg) -- Before the lawsuits started piling up in courtrooms across Connecticut, before his employer accused him of running a “massive Ponzi-like fraud,” and before the FBI showed up, Robert ...